TABLE 1.
Participant demographic information
| Round 1 | Round 2 | |
| Experts in PF | ||
| Subjects n | 45 | 51 |
| Sex | ||
| Male | 16 (36) | 24 (47) |
| Female | 29 (64) | 27 (53) |
| Age years | ||
| 25–35 | 4 (9) | 5 (10) |
| 36–45 | 14 (31) | 15 (29) |
| 46–55 | 15 (33) | 18 (35) |
| Over 55 | 12 (27) | 13 (26) |
| Discipline# | ||
| Physician | 26 (58) | 31 (61) |
| Nurse | 8 (18) | 8 (16) |
| Researcher | 10 (22) | 16 (31) |
| Allied health¶ | 10 (22) | 10 (20) |
| Other | 0 (0) | 0 (0) |
| Multiple disciplines | 9 (20) | 14 (28) |
| Experience in PF care years | ||
| <5 | 4 (9) | 5 (10) |
| 6–10 | 11 (24) | 8 (15) |
| 11–25 | 21 (47) | 26 (51) |
| >25 | 8 (18) | 10 (20) |
| Do not provide direct patient care | 1 (2) | 2 (4) |
| Location | ||
| Asia | 5 (11) | 7 (14) |
| Australia/New Zealand | 15 (33) | 16 (31) |
| Europe | 8 (18) | 12 (23) |
| North America | 16 (36) | 13 (26) |
| South America | 1 (2) | 3 (6) |
| Focus group participants (people living with PF) | ||
| Subjects n | 6 | 6 |
| Sex | ||
| Male | 4 (67) | 4 (67) |
| Female | 2 (33) | 2 (33) |
| Age years | 67.5 (36–72) | 67.5 (36–76) |
| Diagnosis | ||
| IPF | 4 (67) | 4 (67) |
| Non-IPF+ | 2 (33) | 2 (33) |
| Time since diagnosis years | 3.5 (1–5) | 3.5 (1–10) |
| FVC % predicted | 70.5 (39–94) | 82.0 (39–94) |
| TLCO % predicted | 49.5 (19–84) | 49.5 (32–84) |
| Therapy§ | ||
| Antifibrotic | 3 (50) | 4 (67) |
| Immunosuppressantƒ | 2 (33) | 2 (33) |
| Oxygen## | 2 (33) | 2 (33) |
| Location | ||
| (state in Australia) | ||
| Victoria | 6 (100) | 5 (83) |
| Western Australia | 0 (0) | 1 (17) |
Data are presented as n, n (%) or median (range). PF: pulmonary fibrosis; IPF: idiopathic pulmonary fibrosis; FVC: forced vital capacity; TLCO: transfer factor for carbon monoxide. #: healthcare professional participants were allowed to choose multiple disciplines; ¶: allied health professionals included physiotherapist, exercise physiologist and oxygen clinic coordinator and clinical psychologist; +: non-IPF diagnoses included connective tissue disease-associated interstitial lung disease (n=2); §: in Round 1, one participant with PF used both antifibrotic therapy and oxygen therapy, and in Round 2, two used both therapies; ƒ: one participant with PF used mycophenolate mofetil and prednisolone, and the other participant used only mycophenolate mofetil; ##: in Round 1, both participants with PF used oxygen continuously including on exertion, and in Round 2, one used oxygen continuously and one used it only on exertion.